Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_4
1
25%
Ph phase_1
2
50%
Ph phase_3
1
25%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (50.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_4

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

NCT02982187
completedphase_3

To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study

NCT01096017
terminatedphase_1

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

NCT01016951
completedphase_1

Assess Safety, Tolerability and PK of AZD3199 in Japanese

NCT00772759

Clinical Trials (4)

Showing 4 of 4 trials
NCT02982187Phase 4

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

Completed
NCT01096017Phase 3

To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study

Completed
NCT01016951Phase 1

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Terminated
NCT00772759Phase 1

Assess Safety, Tolerability and PK of AZD3199 in Japanese

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4